Heartflow, Inc. (HTFL) SEC Filings & Earnings Calls

Net operating loss increased year-over-year despite revenue growth, indicating ongoing investment spending

“Net operating loss was $17.9 million, compared to $13.7 million in the prior year period” · word for word

Dependence on Reimbursement

“Heartflow Plaque Analysis is currently covered by five of the seven Medicare Administrative Contractors (“MACs”) with the remaining MACs providing coverage on a case-by-case basis and by a majority of commercial payors.” · word for word

Operating Losses

“We have incurred significant operating losses and negative cash flows since our inception, and we expect to continue to incur losses as we grow and continue transitioning to now operating as a public company.” · word for word

Continued net operating loss and reliance on cash reserves.

“Net operating loss of $29.5 million; cash $254.9M.” · word for word

Operating losses and negative cash flows expected to continue

“We have incurred significant operating losses and negative cash flows since our inception, and we expect to continue to incur losses as we grow and transition to now operating as a public company.” · word for word

Dependence on payor coverage for new products

“Heartflow Plaque Analysis is currently covered by five of the seven MACs with the remaining MACs providing coverage on a case-by-case basis and by a majority of commercial payors.” · word for word

Asset impairment charge from facility sublease

“Asset impairment charge consists of a non-cash impairment charge related to the right-of-use asset and leasehold improvements for our Mountain View, California facility. ... recognized an asset impairment charge of $7.5 million during the three months ended March 31, 2026.” · word for word

Key person dependency on CEO

“CEO John C.M. Farquhar is also a director; his departure could impact operations.”

DOJ Investigation

“In October 2025, we and certain of our employees received civil investigative demands (the 'CID') from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.” · word for word

Operating Losses

“We have incurred significant operating losses and negative cash flows since our inception, and we expect to continue to incur losses as we grow.” · word for word

Revenue Concentration

“Heartflow FFR CT Analysis has served as our commercial foundation, representing 98% of our total revenue as of December 31, 2025.” · word for word

Pricing Pressure from Mix Shift

“Partially offset by a reduction in average sales price due to a higher percentage of revenue cases generated from clinic and office-based accounts.” · word for word

Continued net operating losses and reliance on cash reserves ($280.2M) for funding; path to profitability uncertain.

“Net operating loss of $17.8M in Q4 2025; Adjusted EBITDA of ($11.1M); cash burn remains significant.”

Dependence on U.S. FFRCT volume growth and insurance coverage expansion for Plaque Analysis; competitive and reimbursement risks.

“Revenue growth primarily attributable to increase in total U.S. FFRCT volume; Aetna coverage for Plaque Analysis but still early.”

Dependence on single product (Heartflow FFRCT Analysis).

“our dependence on the success of our one product, Heartflow FFRCT Analysis” · word for word

Nascent commercialization of Heartflow Plaque Analysis.

“the nascent nature of the commercialization of Heartflow Plaque Analysis” · word for word

Continued operating losses

“We have incurred significant operating losses and negative cash flows since our inception, and we expect to continue to incur losses as we grow.” · word for word

Dependence on FFR CT Analysis product

“Heartflow FFR CT Analysis has served as our commercial foundation, representing 98% of our total revenue as of September 30, 2025.” · word for word

Pricing pressure from account mix shift

“The increase in revenue was primarily attributable to a 48% increase in revenue case volume, partially offset by a reduction in average sales price due to a higher percentage of revenue cases generated from clinic and office-based accounts.” · word for word

Net loss includes significant noncash charges from warrant and derivative revaluation; these will cease after Q4 2025.

“Net loss $50.9M includes $32.1M noncash warrant charge and $4.8M derivative benefit. Warrants fully net exercised as of Oct 22, 2025.”

Company still operating at a loss; path to profitability not yet clear.

“Net operating loss $15.1M; non-GAAP net operating loss $11.1M; adjusted EBITDA -$9.8M.”